Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05713981 · ClinicalTrials.gov registry record · NA
The Impact of Dry Eye Syndrome on Metrics of Low Contrast Vision Before and After Meibomian Gland Expression
A NA study, sponsored by University of the Incarnate Word.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT05713981 is a NA study that has completed, run by University of the Incarnate Word. The registered enrollment target is 40 participants.
The verdict
NCT05713981, a NA study, has completed, sponsored by University of the Incarnate Word.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
The study aims to determine the impact of Meibomian Gland Dysfunction (MGD) dry eye on low contrast black/white (luminance) and cone color sensitivity performance and improvement in these functions after in-house non-invasive Meibomian gland (MG) expression.
Interventions
- PROCEDURE Meibomian gland (MG) expression
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2023-06-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05713981
The ClinicalTrials.gov registry entry for NCT05713981 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of the Incarnate Word, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Meibomian gland (MG) expression is the first listed.
NCT05713981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05713981 about?
NCT05713981 is a clinical study titled "The Impact of Dry Eye Syndrome on Metrics of Low Contrast Vision Before and After Meibomian Gland Expression". The study aims to determine the impact of Meibomian Gland Dysfunction (MGD) dry eye on low contrast black/white (luminance) and cone color sensitivity performance and improvement in these functions after in-house non-invasive Meibomian gland (MG) expression.
What is the current status of trial NCT05713981?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2023-03-01. Estimated completion is 2023-06-08.
What interventions are being tested in trial NCT05713981?
The interventions under investigation include: Meibomian gland (MG) expression (PROCEDURE).
Who is sponsoring clinical trial NCT05713981?
This trial is sponsored by University of the Incarnate Word, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.